Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07141511
PHASE1

A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults

Sponsor: BeOne Medicines

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) compared to a zanubrutinib capsule and sonrotoclax tablet administered simultaneously and the effect of food on how the body processes the fixed-dose combination tablet.

Official title: A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Evaluate Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332)

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2025-09-24

Completion Date

2026-02-23

Last Updated

2026-04-20

Healthy Volunteers

Yes

Interventions

DRUG

BG-71332

Administered orally

DRUG

Zanubrutinib

Administered orally

DRUG

Sonrotoclax

Administered orally

Locations (1)

Linear Early Phase

Joondalup, Western Australia, Australia